Centessa Pharmaceuticals to Present Preclinical Data for Novel Orexin Receptor 2 (OX2R) Agonist at World Sleep Congress
23 Août 2023 - 11:08PM
Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage
pharmaceutical company focused on discovering and developing
medicines that are transformational for patients, today announced
that preclinical data for ORX750, its first orexin agonist
development candidate, will be featured in an oral presentation at
the World Sleep Congress being held on October 20-25, 2023, in Rio
de Janeiro, Brazil. ORX750 is an orally administered, selective
orexin receptor 2 (OX2R) agonist in preclinical development for the
treatment of narcolepsy and other sleep disorders.
In addition, Sarah Wurts Black, PhD, Head of Biology for
Centessa’s orexin program, will co-chair a symposium at the
Congress focused on the development of orexin receptor
agonists.
“We believe ORX750 has the potential to be a best-in-class
therapy to treat narcolepsy and other sleep disorders, and we are
thrilled with the opportunity to share preclinical data in an oral
presentation at the World Sleep Congress,” said Saurabh Saha, MD,
PhD, Chief Executive Officer of Centessa.
Details of the presentation are as
follows:Title: ORX750, an Oral Selective Orexin
Receptor 2 Agonist, Promotes Wakefulness and Reduces Cataplexy in
the Orexin/Ataxin-3 MouseLink to
Abstract: https://ws2023.abstractserver.com/program/#/details/presentations/1347Ref
number: O25Authors: Sarah Wurts Black,
Tod Steinfeld, Karl Gibson, Gregory R. Ott, Emiliangelo Ratti,
David Grainger, Mario Alberto Accardi, and Deborah S.
HartmanOral Presentation: Wednesday, October 25th
at 10:45 AM (local time)
Symposium: Development of hypocretin/orexin
receptor agonists: a progress report (Co-chairs Sarah Wurts Black
and Thomas S. Kilduff)Link to Symposium
Abstract: https://ws2023.abstractserver.com/program/#/details/sessions/315Title:
Approaches to the discovery and development of hypocretin/orexin
receptor agonistsRef number:
S56Speaker: Sarah Wurts BlackSession
details: Tuesday, October 24th at 3:22 PM (local time)
Additional information about the World Sleep Congress is
available at https://worldsleepcongress.com/program. Centessa plans
to make its presentation available on the Centessa website at
https://investors.centessa.com/events-presentations after the
presentations conclude.
About Centessa
Pharmaceuticals Centessa Pharmaceuticals plc is
a clinical-stage pharmaceutical company that aims to discover and
develop medicines that are transformational for patients. Our
programs span discovery-stage to late-stage development and cover a
range of high-value indications. We operate with the conviction
that each one of our programs has the potential to change the
current treatment paradigm and establish a new standard of care.
For more information, visit http://www.centessa.com/, which does
not form part of this release.
Forward Looking StatementsThis press release
contains forward-looking statements. These statements may be
identified by words such as “may,” “might,” “will,” “could,”
“would,” “should,” “expect,” “intend,” “plan,” “objective,”
“anticipate,” “believe,” “estimate,” “predict,” “potential,”
“continue,” “ongoing,” “aim,” “seek,” and variations of these words
or similar expressions that are intended to identify
forward-looking statements. Any such statements in this press
release that are not statements of historical fact may be deemed to
be forward-looking statements, including statements related to the
Company’s ability to deliver impactful medicines to patients; the
ability of our management team and board to drive execution of the
Company’s portfolio of programs; our asset-centric business model
and the intended advantages and benefits thereof; research and
clinical development plans and the timing thereof; the scope,
progress, results and costs of developing our product candidates or
any other future product candidates; our current expectations
concerning, amongst other things, the development and therapeutic
potential and benefits of our product candidates, including ORX750
and other OX2R agonists; strategy; regulatory matters, including
the timing and likelihood of initiating clinical trials, reporting
clinical trial results, submitting an IND and the success of
obtaining authorizations to initiate or continue clinical trials or
market any products; and the market size and opportunity for our
product candidates. Any forward-looking statements in this press
release are based on our current expectations, estimates and
projections only as of the date of this release and are subject to
a number of risks and uncertainties that could cause actual results
to differ materially and adversely from those set forth in or
implied by such forward-looking statements. These risks and
uncertainties include, but are not limited to, risks related to the
safety and tolerability profile of our product candidates; our
ability to protect and maintain our intellectual property position;
business (including commercial viability), regulatory, economic and
competitive risks, uncertainties, contingencies and assumptions
about the Company; risks inherent in developing product candidates
and technologies; future results from our ongoing and planned
clinical trials; our ability to obtain adequate financing,
including through our financing facility with Oberland, to fund our
planned clinical trials and other expenses; trends in the industry;
the legal and regulatory framework for the industry, including the
receipt and maintenance of clearances to conduct or continue
clinical testing; future expenditures risks related to our
asset-centric corporate model; the risk that any one or more of our
product candidates will not be successfully developed and/or
commercialized; the risk that the results of non-clinical studies
or clinical studies will not be predictive of future results in
connection with future studies; and geo-political risks such as the
Russia-Ukraine war. These and other risks concerning our programs
and operations are described in additional detail in our Annual
Report on Form 10-K, Quarterly Reports on Form 10-Q, and our other
reports, which are on file with the U.S. Securities and Exchange
Commission (SEC). We explicitly disclaim any obligation to update
any forward-looking statements except to the extent required by
law.
Contact:
Kristen K. Sheppard, Esq.SVP of Investor Relations
investors@centessa.com
Centessa Pharmaceuticals (NASDAQ:CNTA)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
Centessa Pharmaceuticals (NASDAQ:CNTA)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024